Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.76 |
| ▸ | HTR2B | P41595 | 3/20 | 0.71 |
| ▸ | HTR2A | P28223 | 6/20 | 0.68 |
| ▸ | HTR1A | P08908 | 4/20 | 0.68 |
| ▸ | HTR2C | P28335 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | HTR1D | P28221 | 2/20 | 0.68 |
| ▸ | HTR1B | P28222 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
| ▸ | HTR6 | P50406 | 2/20 | 0.68 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431365 | 0.86 | GPR84 (1.00) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL178561 | 0.85 | GPR84 (0.78) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL8558403 | 0.84 | SLC6A4 (0.71) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL3976318 | 0.83 | HTR2B (1.00) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL217937 | 0.83 | GPR84 (0.76) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL1723383 | 0.83 | CYP2D6 (0.77) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| 5-Methoxytryptamine SCHEMBL28309973 | 0.83 | HTR1A (0.91) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL8555709 | 0.83 | SLC6A4 (0.69) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL8252894 | 0.82 | HTR2A (0.76) | GPR84HTR2BHTR2AHTR1AHTR2C | |
| SCHEMBL10854107 | 0.81 | GPR84 (0.62) | GPR84HTR2BHTR2AHTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | GPR84 720/4885HTR2B 13/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.